Abstract:Background Minimal data exist on anticoagulation use and timing and the dose of heparin in patients with sepsis, and whether heparin use improves sepsis survival remains largely unclear. This study was performed to assess whether heparin administration would provide a survival advantage in critically ill patients with sepsis. Methods A retrospective cohort study of patients with sepsis in the Medical Information Mart for Intensive Care (MIMIC)-IV database was conducted. Cox proportional hazards model and propensity score matching (PSM) were used to evaluate the outcomes of prophylactic anticoagulation with heparin administered by subcutaneous injection within 48 h of intensive care unit (ICU) admission. The primary outcome was in-hospital mortality. Secondary outcomes included 60-day mortality, length of ICU stay, length of hospital stay and incidence of acute kidney injury (AKI) on day 7. E-Value analysis were used for unmeasured confounding. Results A total of 6646 adult septic patients were included and divided into an early prophylactic heparin group (n = 3211) and a nonheparin group (n = 3435). In-hospital mortality in the heparin therapy group was significantly lower than that in the nonheparin group (prematched 14.7 vs 20.0%, hazard ratio (HR) 0.77, 95% confidence interval (CI) [0.68-0.87], p < 0.001, and postmatched 14.9 vs 18.3%, HR 0.78, 95% CI [0.68-0.89], p < 0.001). Secondary endpoints, including 60-day mortality and length of ICU stay, differed between the heparin and nonheparin groups (p < 0.01). Early prophylactic heparin administration was associated with in-hospital mortality among septic patients in different adjusted covariates (HR 0.71-0.78, p < 0.001), and only administration of five doses of heparin was associated with decreased in-hospital mortality after PSM (HR 0.70, 95% CI 0.56-0.87, p < 0.001). Subgroup analysis showed that heparin use was significantly associated with reduced in-hospital mortality in patients with sepsis-induced coagulopathy, septic shock, sequential organ failure assessment score >= 10, AKI, mechanical ventilation, gram-positive bacterial infection and gram-negative bacterial infection, with HRs of 0.74, 0.70, 0.58, 0.74, 0.73, 0.64 and 0.72, respectively (p <0.001). E-Value analysis suggested robustness to unmeasured confounding. Conclusions This study found an association between early administration prophylactic heparin provided to patients with sepsis and reduced risk-adjusted mortality. A prospective randomized-controlled study should be designed to further assess the relevant findings.

Effect of Low Molecular Weight Heparin on Chinese Patients with Sepsis:A Meta-analysis

Clinical Study of Low Molecular Weight Heparin Therapy for Sepsis

The Efficacy and Safety of Different Anticoagulants on Patients with Severe Sepsis and Derangement of Coagulation: a Protocol for Network Meta-Analysis of Randomised Controlled Trials

Can Heparin Therapy Reduce 28-Day Mortality in Adult Severe Sepsis Patients?

Heparin Therapy and Mortality in Patients with Sepsis: an Observational Study Using a Marginal Structural Cox Model Based on MIMIC-IV Database

Low-molecular-weight heparin therapy reduces 28-day mortality in patients with sepsis-3 by improving inflammation and coagulopathy

Meta-analysis:the clinical effect of low molecular weight heparin on acute pancreatitis in China

Heparin Therapy Reduces 28-Day Mortality in Adult Severe Sepsis Patients: a Systematic Review and Meta-Analysis.

Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis

Dosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective study in a Chinese teaching hospital

Relationship between low molecular weight heparin calcium therapy and prognosis in severe acute kidney injury in sepsis: Mendelian randomized analysis and retrospective study

Low-molecular-weight heparin in the prevention of venous thromboembolism among patients with acute intracerebral hemorrhage: A meta-analysis

Low Molecular Weight Heparin Protects Lung, Renal and Microcirculation Function&nbsp;in Patients with Covid-19 Pneumonia

Low Molecular Weight Heparin Protects Lung, Renal and Microcirculation Function in Patients with Covid-19 Pneumonia

Inverse Relationship of Bleeding Risk with Clot Burden During Pulmonary Embolism Treatment with LMW Heparin.

Early Prophylactic Anticoagulation with Heparin Alleviates Mortality in Critically Ill Patients with Sepsis: a Retrospective Analysis from the MIMIC-IV Database

The Association of Low Molecular Weight Heparin Use and In-hospital Mortality among Patients Hospitalized with COVID-19

Effectiveness of early heparin therapy on outcomes in critically ill patients with sepsis-induced coagulopathy

Impact of early heparin therapy on mortality in critically ill patients with sepsis associated acute kidney injury: a retrospective study from the MIMIC-IV database

Low molecular weight heparin in the treatment of severe acute pancreatitis: a multiple centre prospective clinical study.

Curative effect evaluation on low molecular heparin in sepsis patients with acute kidney injury